Immuno-Oncology
iwNHL 2023 Session V: Expanding the CAR platform in NHL
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 15th December 2023
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who…
Date: 7th December 2023
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 1st December 2023
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…
Date: 24th November 2023
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 17th November 2023
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…
Date: 3rd November 2023
iwAL 2023 Session IV: Transplantation and immunotherapies in AML: improving patient outcomes
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts…
Date: 20th October 2023
Classifying frailty and approaching elderly patients with lymphoma
While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several…
Date: 13th October 2023
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent…
Date: 23rd August 2023
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP). Several mutations, including…
Date: 10th August 2023
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory…
Date: 3rd August 2023
Overcoming barriers to CAR-T therapy: improving access and cost
CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals…
Date: 27th July 2023
